A5103017336- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- Monoclonal and Polyclonal Antibodies Research
- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Peptidase Inhibition and Analysis
- Chemotherapy-induced cardiotoxicity and mitigation
- Ocular Oncology and Treatments
- Melanoma and MAPK Pathways
- BRCA gene mutations in cancer
- Cutaneous Melanoma Detection and Management
- PI3K/AKT/mTOR signaling in cancer
- Cancer, Hypoxia, and Metabolism
- Cancer Immunotherapy and Biomarkers
- Drug Transport and Resistance Mechanisms
- Chemotherapy-related skin toxicity
- Inflammatory Biomarkers in Disease Prognosis
- Metabolomics and Mass Spectrometry Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Pancreatic and Hepatic Oncology Research
- Male Breast Health Studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
Regeneron (United States)
2021-2023
St. Vincent's University Hospital
2013-2022
Royal College of Surgeons in Ireland
2019
Cancer Trials Ireland
2010-2019
Beaumont Hospital
2018-2019
GEICAM – Spanish Breast Cancer Group
2019
Mater Misericordiae University Hospital
2018-2019
Cork University Hospital
2019
University College Dublin
2017-2019
Dublin City University
2019
Abstract Background Renal cell carcinoma patients respond poorly to conventional chemotherapy, this unresponsiveness may be attributable multidrug resistance (MDR). The mechanisms of MDR in renal cancer are not fully understood and the specific contribution ABC transporter proteins which have been implicated chemoresistance various cancers has defined disease. Methods In retrospective study expression two these efflux pumps, namely MDR-1 P-gp (ABCB1) MRP-1 (ABCC1) were studied by...
Abstract Proteus syndrome (PS) is an ultra‐rare disease characterized by progressive, disproportionate, segmental overgrowth caused a somatic gain‐of‐function mutation p.Glu17Lys in the oncogene AKT1 . The has high morbidity and mortality rates due to increased risk for patients develop cancer progressive overgrowth. A teenage patient with severe PS phenotype developed pelvic recurrence of low‐grade serous ovarian carcinoma (LGSOC). Taking into consideration, recent results use AKT...
To report the clinical features and epidemiology of uveal melanoma in Ireland.This was an observational study 253 patients with a new diagnosis between June 2010 December 2015. Main outcome measures included demographics, features, age-adjusted incidence, relative survival, overall distant metastases-free survival.The mean patient age 61.7 years. Tumour location choroidal 82%, ciliochoroidal 9%, iridociliary 2%, iris 7%. Treatment modalities brachytherapy (ruthenium-106 iodine-125 [64%]),...
Background: Activation of the phosphoinositide-3 kinase (PI3K) pathway is a resistance mechanism to anti-human epidermal growth factor receptor 2 (HER2) therapy. This phase Ib trial was conducted determine maximum tolerated dose (MTD) copanlisib, an intravenous (IV) pan-class I PI3K inhibitor, combined with trastuzumab. Methods: Patients advanced HER2-positive breast cancer and disease progression following at least one prior line HER2 therapy in metastatic setting were treated copanlisib...
Serum profiling using mass spectrometry-based proteomic techniques has great potential to detect biomarkers that might improve the management for advanced breast cancer patients. The albuminome previously been investigated as a tool in biomarker discovery, however other high abundant blood proteins are also likely sequester potentially interesting molecules.Affinity resin purified and isolated Transferrin associated bound from normal control patient serum samples were analysed by label-free...
To explore the clinical significance of level HER2/neu gene amplification in a homogenous cohort 33 patients with HER2-positive metastatic breast cancer (MBC) and available tumor samples treated trastuzumab-based regimen, we retrospectively performed dual-color fluorescence in-situ hybridization test correlated them for each patient time-to-progression (TTP) overall survival (OS). We obtained values HER2/chromosome 17 centromere (CEP17) ratio ranging from 2.5 to 21 (median 7.2). At Cox model...
The optimal timing of (neo)adjuvant trastuzumab initiation with respect to chemotherapy and surgery remains undefined.Retrospective analysis a large institutional database HER2-positive patients who received anti-HER2 therapy. We included all Stage I III treated minimum follow up 3 years. date first breast biopsy was recorded as initial diagnosis.A total 506 [adjuvant: 386 (76%)-neo-adjuvant: 120 (24%)] were included. median time-to-first-trastuzumab (TFT) from diagnosis 12 weeks (range...
Optimal evaluation and management of the axilla following neoadjuvant chemotherapy (NAC) in patients with node-positive breast cancer remains controversial. The aim this study was to examine impact receptor phenotype nodal metastases who undergo NAC see whether approach can identify those may be suitable for conservative axillary management.Between 2009 2014, all biopsy-proven disease received were identified from prospectively developed databases. Details had lymph node dissection (ALND)...
The level of HER2/neu amplification may vary widely in breast cancers with alteration. clinical significance this phenomenon is still unclear. This study was aimed to explore the primary tumours and metastases HER2-positive metastatic cancer (MBC) its potential impact on survival after a trastuzumab-containing therapy.We retrospectively identified MBC patients treated therapy performed dual-colour FISH tumour samples from either and/or metastasis central laboratory.We retrieved 110 91...
Combining bevacizumab and chemotherapy produced superior response rates compared with alone in metastatic breast cancer. As may cause hypertension (HTN) increase the risk of cardiac failure, we performed a pilot study to evaluate feasibility toxicity non-anthracycline-containing combination docetaxel cyclophosphamide early stage cancer patients.Treatment consisted four 3-weekly cycles (75/600 mg/m2). Bevacizumab was administered 15 mg/kg intravenously on day 1, then every 3 weeks total 18...
Abstract Background: The addition of trastuzumab (H) to pre-operative chemotherapy in H+BC increases the rate pathological complete remission (pCR). H causes cardiac toxicity, especially when given with anthracyclines (Anth). TCH is a widely used adjuvant regimen decreased toxiciy. We reported that produces pCR 40% non-randomised pts H+BC. Lapatinib an alternative HER2 antagonist, which responses following failure, and has been augment activity combination. studied non-Anth regimens v TCL...
9085 Background: In the Phase 3, EMPOWER-Lung 1 study, cemiplimab monotherapy provided significant survival benefit and an acceptable safety profile vs chemotherapy in patients with advanced NSCLC PD-L1 ≥50%. included brain metastases at baseline who are typically underrepresented clinical trials. Other published exploratory analyses single-cohort studies suggest from immunotherapy this patient population. Here, we present subgroup analysis of metastasis 1. Methods: Patients were randomized...
To assess the activity and tolerability of combination mitomycin C capecitabine in patients with metastatic colorectal cancer after failure irinotecan oxaliplatin-containing regimens.We retrospectively reviewed 28 pretreated advanced who had been treated C, 6 mg/m2 on day 1, capecitabine, 1900 days 1-14, every 3 weeks. Tumor assessment was performed cycles, toxicity assessed at each cycle.Main patient characteristics were median age, 61 years (range, 35-73); male/female ratio, 16/12; single...